anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Antibiotics are mainly used for disease treatment and prevention, and β-receptor agonists are mainly used in the clinical treatment of respiratory diseases. Both types of drugs are also widely used in animal husbandry and aquaculture to promote animal growth and prevent disease. These drugs enter the human body through many routes and cause harm to human health. Teenagers are in a critical period of growth and development, and long-term antibiotic exposure may have adverse effects on their bodies. In this study, 442 teenagers aged 11-15 years were recruited from a middle school to investigate the body burden of various antibiotics and β-receptor agonists. The seven categories of antibiotics, including five macrolides, four tetracyclines, 10 quinolones, 11 sulfonamides, three β-lactams, one quinoxaline, and one lincosamide, and four β-receptor agonists were determined by isotope dilution and solid phase extraction coupled with ultra performance liquid chromatography-tandem mass spectrometry. Analyte levels were corrected using urine creatinine, and detection rates were used for data analysis. Pearson's chi-squared test was used to analyze the correlations between detection rate and gender, age, or body mass index (BMI). Logistic regression was used to evaluate the correlation between detection rate and different groups after adjusting for confounding factors. The results showed that 397 teenagers had at least one antibiotic or β-receptor agonist in their urine, with a total detection rate of 89.8%. A total of 29 antibiotics and β-receptor agonists were detected, and the detection rate of each compound ranged from 0.2% to 59.0%. Doxycycline, oxytetracycline, and azithromycin were the top three drugs with the highest detection rates (59.0%, 56.1%, and 34.6%, respectively). Tetracyclines and macrolides were the two antibiotic categories detected most often, with detection rates of 81.9% and 42.3%, respectively. Among the antibiotics investigated, preferred veterinary antibiotics (PVAs) had the highest detection rate (85.1%), followed by human antibiotics (HAs) (41.0%). The overall detection rate of β-receptor agonists was 2.7%. Statistical analysis showed that the male was prone to be exposed to tetracycline antibiotics (odds ratio (OR)=2.17). The detection rates of macrolides differed among the different age groups and were higher in those aged 12-13 years than in those aged 11 years. As the BMI of the teenagers increased, the detection rate of macrolides gradually increased. After adjusting for age and gender, teenagers with obesity were found to be 2.35 times more likely to be exposed to macrolides than those with a normal weight. The findings suggest that teenagers are generally exposed to low levels of antibiotics, that food and the environment may be the main sources of antibiotic exposure in teenagers, and that macrolide exposure may be associated with adolescent obesity.
BACKGROUND: The prognostic value of traditional clinical indicators for locally recurrent nasopharyngeal carcinoma is limited because of their inability to reflect intratumor heterogeneity. We aimed to develop a radiomic signature to reveal tumor immune heterogeneity and predict survival in locally recurrent nasopharyngeal carcinoma.
METHODS: This multicenter, retrospective study included 921 patients with locally recurrent nasopharyngeal carcinoma. A machine learning signature and nomogram based on pretreatment magnetic resonance imaging features were developed for predicting overall survival in a training cohort and validated in 2 independent cohorts. A clinical nomogram and an integrated nomogram were constructed for comparison. Nomogram performance was evaluated by concordance index and receiver operating characteristic curve analysis. Accordingly, patients were classified into risk groups. The biological characteristics and immune infiltration of the signature were explored by RNA-sequencing analysis.
RESULTS: The machine learning signature and nomogram demonstrated comparable prognostic ability to a clinical nomogram, achieving concordance indexes of 0.729, 0.718, and 0.731 in the training, internal, and external validation cohorts, respectively. Integration of the signature and clinical variables statistically improved the predictive performance. The proposed signature effectively distinguished patients between risk groups with statistically distinct overall survival rates. Subgroup analysis indicated the recommendation of local salvage treatments for low-risk patients. Exploratory RNA-sequencing analysis revealed differences in interferon response and lymphocyte infiltration between risk groups.
CONCLUSIONS: A magnetic resonance imaging-based radiomic signature predicted overall survival more accurately. The proposed signature associated with tumor immune heterogeneity may serve as a valuable tool to facilitate prognostic stratification and guide individualized management for locally recurrent nasopharyngeal carcinoma patients.
Hypertension is a common side effect of cyclosporine capsules therapy (see ADVERSE REACTIONS). Mild or moderate hypertension is more frequently encountered than severe hypertension and the incidence decreases over time. Antihypertensive therapy may be required. Control of blood pressure can be accomplished with any of the common antihypertensive agents. However, since cyclosporine may cause hyperkalemia, potassium-sparing diuretics should not be used. While calcium antagonists can be effective agents in treating cyclosporine-associated hypertension, care should be taken since interference with cyclosporine metabolism may require a dosage adjustment (see Drug Interactions).
Parents who take part in the research will arrive at their scheduled appointment. If parents have not brought their signed consent form, they will be asked to sign it in clinic. This consent form also will contain questions about infant and parent demographics as well as socio-demographic background details, which the parent is asked to fill in. Parents will be guided into a separate treatment room, which contains a treatment table behind a screen. A qualified osteopathic practitioner will take the case history for each infant who then receives a physical assessment. After that, the parent will have to give consent for the infant to be further involved in the study and to be treated. This procedure will be done without the screen, so that the parent can see what is going on. Then the infant is placed behind the screen on the treatment couch. The osteopath will be informed by the Research Assistant whether the infant is allocated (via random allocation list) to receiving either no intervention or OMT for 20 min. For infants in the OMT group, the osteopathic practitioner will carry out the treatment procedure, and the Research Assistant will act as an intermediary. Infants in the 'no intervention' group will just lie on the couch, without being touched by the osteopath.

At all times, the screen is placed between the parent and their infant on the treatment couch, so that the parent will not be able to see their infant. However, the intermediary is placed in a way so that the parent can see and communicate with them, and the intermediary can observe what is happening behind the screen with the infant. The osteopathic practitioner will be present at all times in both groups, to safeguard the infant from rolling off the couch in case the infant does not receive any intervention. In addition, if the infant starts crying, the osteopathic practitioner will try to calm the infant down (for infants in the OMT group the osteopath will use toys and touch, in the 'no intervention' group toys only will be used, no touch), but if necessary will ask the parent to come round the screen and help in calming their infant down. If this is the case, the osteopathic practitioner stops the treatment, if the infant is placed in the OMT group, and waits until the infant is calmed down so that the parent can go back behind the screen. This procedure will be repeated until 20 min of the treatment period are over. The same procedure applies for the 'no intervention group', except that the osteopath will not touch the infant, rather tries to calm it down with toys or eventually will call the parent in to do the calming. After the 20mins of 'treatment period', parents of infants in both groups are required to fill in the blinding success and acceptability questionnaire.
A method of manufacturing a two-layer nanocellulose composite sheet is provided. The two-layer nanocellulose composite sheet is comprised of a moisturized nanocellulose material and a fabric. The method includes the steps of dispersing a diluted nanocellulose suspension onto a fabric, and partially drying the diluted nanocellulose suspension until the diluted nanocellulose suspension is transformed to the moisturized nanocellulose material bonded to the fabric. Thereby, a surface of the moisturized nanocellulose material is bonded by mechanical adhesion to a surface of the fabric. The nanocellulose composite sheet manufactured by this method has contour conformability, excellent skin-adhesion, and high capacity for moisture retention and release, and is ideal for dermatological treatments. An apparatus for manufacturing the nanocellulose composite sheet is also provided.
This study explores the psychological impact of platelet-rich plasma (PRP) treatment for hair loss. PRP, an autologous plasma enriched with platelets, has gained recognition in aesthetic and regenerative medicine for its potential to facilitate tissue healing and regeneration through the release of growth factors. However, concerns arise regarding the lack of standardized protocols for PRP preparation and characterization, including platelet counts and active substance concentrations. Additionally, the concentration of leukocytes and the platelet-to-leukocyte ratio in PRP are crucial factors that can affect treatment outcomes. Further analysis is necessary to establish reliable conclusions about the applications of PRP. LEVEL OF EVIDENCE V: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
<P>PROBLEM TO BE SOLVED: To provide a food composition which is suitable as diet food and medical food, producing a long-lasting feeling of fullness, and giving high satisfaction as a meal.  <P>SOLUTION: This powdery or liquid food composition contains protein, mineral and vitamin, and also a thickener, and at least 2 wt.% of free amino acid based on solid content. The thickener is at least one kind selected from among xanthan gum, Cyamoposis Gum, Locust bean gum, tamarind seed gum, Tara gum, alginic acid (Na), gellan gum, pectin, and carrageenan. The free amino acid is at least one kind selected from among isoleucine, leucine, valine, threonine, lysine, histidine, methionine, phenylalanine, tryptophane, glycine, alanine, proline, arginine, glutamine, asparagine, glutamic acid, and aspartic acid. For the case of the liquid composition, the viscosity is adjusted to be 300-1,000 mPa second.  <P>COPYRIGHT: (C)2009,JPO&INPIT
OBJECTIVES: Talquetamab is a newly approved bispecific antibody targeting the CD3 receptor on T cells and a receptor, G protein-coupled receptor family C group 5 member D (GPRC5D), highly expressed on multiple myeloma (MM) cells. In addition to immune therapy-related adverse events (AEs) associated with bispecific antibody therapies, talquetamab is associated with unique skin/nail and oral GPRC5D-related side effects that require additional supportive care. This review provides clinical management strategies for talquetamab based on oncology nurses' experience during the MonumenTAL-1 (NCT03399799/NCT04634552) clinical trial. The objective of this review is to raise awareness among nurses and patients to better understand and manage the side effects associated with talquetamab treatment in order to optimize patient outcomes.
DATA SOURCES: MonumenTAL-1 is a phase 1/2 clinical trial of talquetamab in patients with relapsed/refractory MM who are triple-class exposed. Details on overall response, safety, and AE incidence and occurrence were previously published. Management strategies for the T-cell-related and unique GPRC5D-related AEs were collected from oncology nurses from different study sites.
CONCLUSION: Talquetamab has shown overall response rates of >71% in patients with relapsed/refractory MM in the MonumenTAL-1 study. AEs were low grade and predictable; few led to study discontinuation.
IMPLICATIONS FOR NURSING PRACTICE: Oncology nurses have specialized knowledge of treatment administration monitoring based on their participation in the MonumenTAL-1 trial. This review provides information for nurses in both the academic and community settings on how to monitor, counsel, and support patients, which will in turn improve patients' quality of life and overall survival.
1. Pharmaceutical gastric and/or duodenal adhesive dosage form characterized in that the form is obtained by coating a composition, which comprises a medicament acting at the stomach and/or duodenum and water insoluble cellulose polymer (I), polymer (II), having adhesive capacity onto the surface of the mucosa of a digestive tract under acid conditions and separates from the mucosa of the digestive tract in neutral or alkaline conditions, wherein said polymer is obtained from acrylic acid and/or methacrylic acid and carbon acid ester. 2. Pharmaceutical dosage form according to claim 1, characterized in that the polymer (II) is so-polymer of methacrylic acid and methacrylate. 3. Pharmaceutical dosage form according to claim 1, characterized in that the polymer (I) is ethylcellulose. 4. Pharmaceutical dosage form according to claim 2, characterized in that the polymer (I) is ethylcellulose. 5. Pharmaceutical dosage form according to claim 1, characterized in that the polymer (II) is conditions is soluble in a solution of at least pH 4.
Stroke is one of the most common and debilitating neurological conditions worldwide. Those who survive experience motor, sensory, speech, vision, and/or cognitive deficits that severely limit remaining quality of life. While rehabilitation programs can help improve patients' symptoms, recovery is often limited, and patients frequently continue to experience impairments in functional status. In this review, invasive neuromodulation techniques to augment the effects of conventional rehabilitation methods are described, including vagus nerve stimulation (VNS), deep brain stimulation (DBS) and brain-computer interfaces (BCIs). In addition, the evidence base for each of these techniques, pivotal trials, and future directions are explored. Finally, emerging technologies such as functional near-infrared spectroscopy (fNIRS) and the shift to artificial intelligence-enabled implants and wearables are examined. While the field of implantable devices for chronic stroke recovery is still in a nascent stage, the data reviewed are suggestive of immense potential for reducing the impact and impairment from this globally prevalent disorder.
The present invention relates to novel antibodies reactive with human carcinoma cells. More particularly, the antibodies of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; and a F(ab')2 fragment of BR96. These antibodies are reactive with a cell membrane antigen on the surface of human carcinomas. The antibodies display a high degree of selectivity for carcinoma cells and possess the ability to mediate ADCC and CDC activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.
This randomized, double-blind, placebo-controlled study intends to recruit 136 qualified sarcopenias with spleen-asthenia syndrome. The trial will be conducted at the Second People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine in Fujian Province, China. All subjects will be required to fill in baseline information before enrollment to determine the general situation of patients before randomization. Subsequently, the subjects were randomly divided into two groups in a 1:1 ratio: the yam pill group (n = 68) and the placebo group (n =68), randomized sequences were provided by statistical experts who were not involved throughout the trial. Among them, the yam pill is a traditional Chinese medicine formula pill composed of yam, white art, and ginseng, and the placebo is mainly composed of corn starch, which is entirely consistent with the appearance, shape, size, color, specification, packaging and label of yam pill. The Chinese medicine formulations of the two groups were provided in the form of a pill and rice soup delivery (3 times a day, 5 days/week, a total of 24 weeks). In addition, to improve patient compliance during the intervention period, patients in both groups were required to attend a health education lecture once a month, and both groups were followed up for 24 weeks after the intervention.

The four-time points were compared before the intervention (0 weeks), during the intervention (after the end of the 12th week), at the end of the intervention (after the end of the 24th week), and during the follow-up (after the end of the 48th week). The main index was the changes in muscle mass ( 24 weeks minus baseline), and the secondary index was the changes in muscle strength (grip strength; 5 times chair stand test); Physical function (e.g. 6-min walking test, gait speed, time-up-go-test); cognitive function, quality of life and clinical efficacy of traditional Chinese medicine were investigated with the forms of questionnaires to explore the clinical effectiveness of yam pills on patients with spleen asthenia syndrome. Secondly, near-infrared spectral imaging (fNIRS) was used to explore whether the improvement of clinical efficacy caused by yam pills after 24 weeks of intervention was related to the hemodynamic changes in the prefrontal cortex and motor cortex brain region based on the dual task of motor cognition. Subsequently, 16S-rRNA sequencing and non-targeted metabolomics were used to explore whether the improvement of clinical efficacy caused by Yam pills after 24 weeks of intervention was related to the regulation of intestinal flora and its metabolites, to finally clarify the musculus-brain crosstalk during the intervention process and explore its potential mechanism of action.
OBJECTIVE: A recent study leveraging machine learning methods found that postpartum hemorrhage (PPH) can be predicted accurately at the time of labor admission in the U.S. Consortium for Safe Labor (CSL) dataset, with a C-statistic as high as 0.93. These CSL models were developed in older data (2002-2008) and used an estimated blood loss (EBL) of ≥1,000 mL to define PPH. We sought to externally validate these models using a more recent cohort of births where blood loss was measured using quantitative blood loss (QBL) methods.
STUDY DESIGN: Using data from 5,261 deliveries between February 1, 2019 and May 11, 2020 at a single tertiary hospital, we mapped our electronic health record (EHR) data to the 55 predictors described in previously published CSL models. PPH was defined as QBL ≥1,000 mL within 24 hours after delivery. Model discrimination and calibration of the four CSL models were measured using our cohort. In a secondary analysis, we fit new models in our study cohort using the same predictors and algorithms as the original CSL models.
RESULTS: The original study cohort had a substantially lower rate of PPH, 4.8% (7,279/228,438) versus 25% (1,321/5,261), possibly due to differences in measurement. The CSL models had lower discrimination in our study cohort, with a C-statistic as high as 0.57 (logistic regression). Models refit in our study cohort achieved better discrimination, with a C-statistic as high as 0.64 (random forest). Calibration improved in the refit models as compared with the original models.
CONCLUSION: The CSL models' accuracy was lower in a contemporary EHR where PPH is assessed using QBL. As institutions continue to adopt QBL methods, further data are needed to understand the differences between EBL and QBL to enable accurate prediction of PPH.
KEY POINTS: · Machine learning methods may help predict PPH.. · EBL models do not generalize when QBL is used.. · Blood loss estimation alters model accuracy..
Systems for coordinating and providing blood sample analysis are described herein. The system comprises a web server implemented as a computer system in communication with a computer network. The system is configured to perform certain operations in response to messages received from devices over the Internet. The system comprises interfaces (e.g., communication ports and supporting software) for communication with client devices external to the server. The system is configured to receive an order for a blood sample an analysis. To that end, the web server is in communication with a physician's client computer device via a communication network. The system implements computers and equipment that receive requests for blood tests and provide related services including, for example, automated and secure testing and reports of tests.
Behavioral interventions for health promotion are widely used for preventive health practices. There are many studies on topics such as smoking, diet, obesity and oral care. However, we see that studies improving physical activity behavior in children are limited. Considering that physical activity is an important health-related behavior that should be acquired from childhood, we predict that studies on this subject will have an important place in the literature. In addition, it is stated in the guidelines that while the effect of physical activity behavior on health-related parameters in children is clear, more evidence is still needed on its effect on cognitive functions. With our study, we aim to examine the sustainability, physical and psychosocial effects of developing physical activity behavior in children using the 5A model and contribute to the literature.
The present invention relates to an olanzapine oral disintegration tablet and a preparation method thereof. The olanzapine oral disintegration tablet comprises: olanzapine, mannitol, and calcium hydrogen phosphate. The olanzapine oral disintegration tablet uses the olanzapine as the raw material, comprises one or more pharmaceutically acceptable excipients and is prepared by a direct compression. The olanzapine oral disintegration tablet can be quickly disintegrated in vitro, and quickly and uniformly disintegrated and dispersed, and is slightly sweet and tastes good. The olanzapine oral disintegration tablet is conveniently taken, and is especially suitable for the patients with emergency in dysphagia or special environment such as the elderly, children, and coma patient. The olanzapine oral disintegration tablet has the advantages of simple preparation process and low cost, and is suitable for industrialized production.